[CAS NO. 2130958-55-1] Firmonertinibmesylate

Name: Firmonertinibmesylate
Brand: Arctom Scientific
SKU: AS940581

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2130958-55-1]

Distributor

Catalog

AS940581

Brand

Arctom Scientific

CAS

2130958-55-1

DESCRIPTION [2130958-55-1]

Overview

MDL	MFCD31746903
Molecular Weight	664.70
Molecular Formula	C29H35F3N8O5S
SMILES	C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O.CS(=O)(O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Patent. US20220177473A1.

Summary

Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR . Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) ^[1] .

IC50 & Target

EGFR

In Vitro

Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05165355	Tongji University	NSCLC\|EGF-R Positive Non-Small Cell Lung Cancer	December 28, 2021	Phase 2
NCT05465343	Peking Union Medical College	Furmonertinib\|EGFR-mutation\|NSCLC\|Brain Metastases	July 11, 2022	Phase 2
NCT05209256	The First Affiliated Hospital of Henan University of Science and Technology	NSCLC	March 1, 2022	Phase 2\|Phase 3
NCT05255406	Fudan University\|Allist Pharmaceuticals, Inc.	Non-Small-Cell Lung Cancer	December 9, 2021	Phase 2
NCT03127449	Allist Pharmaceuticals, Inc.	Advanced NSCLC	June 1, 2017	Not Applicable
NCT04965831	Tianjin Medical University Cancer Institute and Hospital\|Allist Pharmaceuticals, Inc.	Lung Adenocarcinoma	August 1, 2021	Phase 2
NCT04970693	Sun Yat-sen University	Non-small Cell Lung Cancer\|Oligoprogressive	June 1, 2021	Phase 2
NCT05364073	ArriVent BioPharma, Inc.	Non-Small Cell Lung Cancer\|Carcinoma, Non-Small-Cell Lung\|Carcinoma, Bronchogenic\|Bronchial Neoplasms\|Lung Neoplasms\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Neoplasms by Site\|Neoplasms\|Lung Diseases\|Respiratory Tract Diseases\|Antineoplastic Agents\|Enzyme Inhibitors\|Molecular Mechanisms of Pharmacological Action\|Protein Kinase Inhibitors	June 30, 2022	Phase 1
NCT04858958	Allist Pharmaceuticals, Inc.	NSCLC	August 10, 2020	Phase 1
NCT03452592	Allist Pharmaceuticals, Inc.	Advanced NSCLC Patients With T790M	April 30, 2018	Phase 2
NCT05379803	Hunan Province Tumor Hospital	Non-Small Cell Lung Cancer	May 1, 2022	Phase 2
NCT04895930	Shanghai Chest Hospital\|Allist Pharmaceuticals, Inc.	Non-Small-Cell Lung Cancer	October 12, 2021	Phase 2
NCT05503667	Shanghai Pulmonary Hospital, Shanghai, China	Lung Adenocarcinoma Stage III\|Lung Adenocarcinoma Stage IV\|EGFR Gene Mutation	February 1, 2022	Phase 2
NCT05445310	Peking Union Medical College Hospital	Non-small Cell Lung Cancer	July 1, 2022	Phase 2
NCT05466149	Allist Pharmaceuticals, Inc.	NSCLC	August 2022	Phase 2
NCT05548348	Chongqing University Cancer Hospital\|Army Specialty Medical Center\|The Second Affilicated Hospital of Chongqing Medical University	Non-small Cell Lung Cancer\|EGFR G719X\|EGFR L861Q\|EGFR S768I	September 26, 2022	Phase 2
NCT05334277	Sun Yat-sen University\|Allist Pharmaceuticals, Inc.\|GeneCast Biotechnology Co., Ltd.	Non-small Cell Lung Cancer	May 6, 2022	Phase 2
NCT03787992	Allist Pharmaceuticals, Inc.	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	May 30, 2019	Phase 3
NCT05607550	ArriVent BioPharma, Inc.\|Allist Pharmaceuticals, Inc.	Non-Small Cell Lung Cancer\|Carcinoma, Non-Small-Cell Lung\|Carcinoma, Bronchogenic\|Bronchial Neoplasms\|Lung Neoplasms\|Respiratory Tract Neoplasms\|Neoplasms by Site\|Neoplasms\|Lung Diseases\|Respiratory Tract Diseases\|Antineoplastic Agents\|Enzyme Inhibitors\|Molecular Mechanisms of Pharmacological Action\|Protein Kinase Inhibitors	December 15, 2022	Phase 3
NCT04853342	Allist Pharmaceuticals, Inc.	Non-small Cell Lung Carcinoma	April 17, 2021	Phase 3
NCT04982900	Ruijin Hospital\|Fujian Medical University Union Hospital\|First Affiliated Hospital of Zhejiang University\|Second Affiliated Hospital, School of Medicine, Zhejiang University\|Tang-Du Hospital\|The First Affiliated Hospital of Nanchang University	Multiple Primary Lung Cancers	October 1, 2021	Phase 2
NCT04958967	Allist Pharmaceuticals, Inc.	NSCLC	October 1, 2021	Phase 1
NCT02973763	Allist Pharmaceuticals, Inc.	NSCLC	December 30, 2016	Phase 1
NCT05079022	Peking University People´s Hospital\|Beijing CSCO-Allist Cancer Research Foundation\|Shanghai Allist Pharmaceutical Technology Co., Ltd.\|Guangzhou Burning Rock Medical Examination Institute Co., Ltd.	Adenocarcinoma of Lung	October 2021	Phase 1\|Phase 2
NCT03926182	Allist Pharmaceuticals, Inc.	Healthy Male Volunteers	February 19, 2019	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMSO : 5 mg/mL ( 7.52 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5044 mL	7.5222 mL	15.0444 mL
5 mM	0.3009 mL	1.5044 mL	3.0089 mL
10 mM	---	---	---

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.